Dyadic International And 2 Other US Penny Stocks To Watch

In This Article:

The U.S. stock market recently experienced a significant downturn, with major indices like the Dow Jones Industrial Average and the S&P 500 suffering their worst one-day losses in months due to concerns over interest rate policies. In this context, investors might consider exploring alternative investment areas such as penny stocks, which remain a relevant opportunity despite being considered somewhat niche today. These stocks often represent smaller or newer companies and can offer substantial growth potential when supported by strong financial foundations.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$3.95

$1.93B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$108.87M

★★★★★★

BAB (OTCPK:BABB)

$0.905

$6.59M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.78

$87.36M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Permianville Royalty Trust (NYSE:PVL)

$1.445

$47.52M

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$0.80

$77.26M

★★★★★☆

Smith Micro Software (NasdaqCM:SMSI)

$0.9632

$17.69M

★★★★★☆

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.58

$381.2M

★★★★☆☆

Click here to see the full list of 739 stocks from our US Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Dyadic International

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Dyadic International, Inc. is a biotechnology platform company that develops, produces, and sells enzymes and other proteins both in the United States and internationally, with a market cap of $42.90 million.

Operations: The company generates its revenue primarily from its biotechnology segment, amounting to $3.36 million.

Market Cap: $42.9M

Dyadic International, Inc., a biotechnology company with a market cap of US$42.90 million, reported significant revenue growth for the third quarter of 2024, reaching US$1.96 million from US$0.40 million the previous year. Despite this increase, the company remains unprofitable with a negative return on equity and is not expected to achieve profitability in the near term. Dyadic has more cash than debt and maintains sufficient cash runway for over a year at current free cash flow levels. However, shareholders have experienced dilution recently due to an increase in shares outstanding by 2.7%.

NasdaqCM:DYAI Revenue & Expenses Breakdown as at Dec 2024
NasdaqCM:DYAI Revenue & Expenses Breakdown as at Dec 2024

WM Technology

Simply Wall St Financial Health Rating: ★★★★★★